Signatera Receives Major Regulatory Milestone in Europe

Advances in cancer care don't always come in the form of a new treatment. Sometimes they come from better ways to monitor cancer and help guide decisions throughout a patient's journey.

Recently, Natera announced that its personalized molecular residual disease (MRD) test, Signatera™, has received certification under the European Union's In Vitro Diagnostic Regulation (IVDR). This makes Signatera the first personalized MRD test for solid tumors to receive this certification in the European Union. The milestone follows two other significant achievements this year: becoming the first PMDA-approved MRD test in Japan and the first FDA-approved personalized MRD test to help guide treatment decisions in the United States.

So, what does that actually mean?

MRD testing looks for tiny amounts of circulating tumor DNA (ctDNA) that may remain in the body after cancer treatment. In some cancers, these tests can help physicians monitor for recurrence, assess how well treatment is working, and make more informed decisions about a patient's care. Signatera is a personalized blood test, meaning it is designed using the unique genetic makeup of an individual's tumor.

The new IVDR certification means Signatera has met the European Union's rigorous standards for safety, quality, and clinical performance. It also helps make the test more accessible for clinical trials and patients throughout Europe while supporting continued research into personalized cancer care.

For the testicular cancer community, this news is especially meaningful because ctDNA and MRD testing continue to be an exciting area of research. At TCAF, we've previously shared information about how Signatera is being studied as a personalized surveillance tool for detecting relapse in testicular cancer. Research has shown its potential to identify recurrence earlier than traditional tumor markers in some patients, though additional studies are ongoing. While MRD testing is not currently considered standard of care for testicular cancer, researchers continue to explore how these technologies may improve surveillance and help inform treatment decisions in the future.

At the Testicular Cancer Awareness Foundation, we're committed to keeping our community informed about meaningful developments in cancer research and care. Natera has been a valued partner of TCAF, supporting our mission to educate, raise awareness, and empower patients and survivors. While this announcement extends beyond testicular cancer specifically, it represents another step forward in the growing field of personalized medicine. We'll continue sharing research and innovations that may help shape the future of cancer care and what they could mean for the testicular cancer community.

To learn more about this announcement, read the full news release from Natera. You can also learn more about ctDNA and relapse surveillance in testicular cancer by visiting TCAF's Relapse Surveillance resource.